NCT03479450

Brief Summary

The traditional concept believes that the etiology of neonatal respiratory distress syndrome (RDS) is immature development of lung,especially the surfactant synthesis system,and RDS is still one of the major causes of mortality and morbidity in newborns, especially premature infants.In recent years, using pulmonary surfactant replacement therapy (PS treatment) in the treatment of respiratory distress syndrome (RDS) is a major breakthrough in neonatal medicine.Combined with clinical practice and experience,and through Meta analysis of related randomized controlled trials (RCTs),it confirms that natural surfactant treatment can reduce mortality,the incidence of pulmonary air leaks (pneumothorax and interstitial lung emphysema),and the incidence of bronchopulmonary dysplasia (BPD) or 28-day-old mortality.For RDS in preterm infants whose gestation is \<35 weeks ,surfactant replacement therapy is also more effective than in nearly term and full term infants.Therefore, in the analysis of cases of different gestational age groups,the investigators should focus on the study of premature infants cases.Due to less relevant research for using PS treatment to cure newborn RDS in high altitude area,this retrospective study conducts statistics and analysis of recently three-year cases in some hospital of high altitude area,to explore the treatment effect of the high altitude region and the impact of altitude on the treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 18, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 27, 2018

Completed
1.9 years until next milestone

Study Start

First participant enrolled

March 1, 2020

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

February 17, 2021

Status Verified

February 1, 2021

Enrollment Period

2.8 years

First QC Date

March 18, 2018

Last Update Submit

February 14, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • bronchopulmonary dysplasia(BPD)

    the incidence of BPD in infants with neonatal neonatal RDS

    before discharge or 36 weeks' gestational age

  • death

    the incidence of BPD in infants with neonatal RDS

    before discharge or 36 weeks' gestational age

Secondary Outcomes (2)

  • intraventriclular hemorrhage(IVH)

    before discharge or 36 weeks' gestational age

  • necrotizing enterocolitis(NEC)

    before discharge or 36 weeks' gestational age

Interventions

surfactant is given when neonatal respiratory distress syndrome is diagnosed

Eligibility Criteria

Age10 Minutes - 1 Day
Sexall
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

the preterm infants less than 37 weeks and diagnosed with NRDS were included in the study.

You may qualify if:

  • the preterm infants less than 37 weeks were included in the study;diagnosed with NRDS

You may not qualify if:

  • parents' rejecting to join;major congenital abnormalities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Pediatrics, Daping Hospital, Third Military Medical University

Chongqing, Chongqing Municipality, 400042, China

RECRUITING

MeSH Terms

Interventions

Surface-Active Agents

Intervention Hierarchy (Ancestors)

Specialty Uses of ChemicalsChemical Actions and Uses

Central Study Contacts

Chen Long, PhD,MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 18, 2018

First Posted

March 27, 2018

Study Start

March 1, 2020

Primary Completion

December 1, 2022

Study Completion

December 1, 2022

Last Updated

February 17, 2021

Record last verified: 2021-02

Locations